The fourth-quarter 2024 earnings cycle is here, with quite a few healthcare companies having reported results. Early reports ...

Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail ...

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

Cardinal's pharmaceutical and specialty solutions segment distributes branded, generic, and specialty drugs and over-the-counter healthcare and consumer products. Cardinal plays a central role in the ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Cencora, Inc. COR is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches.

Buying $100 In COR: If an investor had bought $100 of COR stock 10 years ago, it would be worth $510.85 today based on a price of $256.50 for COR at the time of writing.

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wells Fargo analyst Stephen Baxter raised the firm’s price target on Cencora (COR) to $251 from $237 and keeps an Equal Weight rating on the ...

Harrow's "Harrow Cares" program, in partnership with Cencora, aims to improve access and affordability of eye care treatments ...

Wells Fargo analyst Stephen Baxter maintained a Hold rating on Cencora (COR – Research Report) yesterday and set a price target of $251.00. The ...

Cencora, Inc. (NYSE:COR – Get Free Report)’s share price reached a new 52-week high on Monday after JPMorgan Chase & Co.